News

Getting personal

BY Barbara White-Sax

Industry experts say growth in the photo department will come from personalized products. “The photo category of the future is in user-generated content,” said Steve Giordano Jr., president of Lucidiom. “Customers should be able to go into a drug store and purchase personalized invitations, banners and thank you notes for a party.”

Retailers, Giordano said, have to go deep in the category to be competitive. That means offering everything from invitations and sticky notes to photobooks.

Photobooks have shown annual gains of about 8%. “Photobooks take some creativity to produce, and they are not a 4×6 replacement,” said Gary Pageau, a spokesman for the Photo Marketing Association. “The model of standing at a kiosk for a long time is under challenge, so software that makes it easier to produce a great-looking photobook [will drive growth in the future].”

Greeting card applications are a promising area of growth for photo processing. Folded greeting card sales were up 35% at Lucidiom. Customized greeting cards often sell for less than the traditional cards in the greeting card aisle, but the industry hasn’t done a good job of communicating that to consumers.

Online order/retail pickup is growing 8% per year. The ability to access photos on Facebook has provided some growth to kiosk printing. “Images [on] Facebook can now be accessed at many 
kiosks, providing … another source of images,” Pageau said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Pawlenty joins RedPrairie board

BY Michael Johnsen

ATLANTA — RedPrairie, a global supply chain and retail technology provider, on Tuesday announced the appointment of former Minnesota governor Tim Pawlenty to RedPrairie’s board of directors.

Pawlenty is the keynote speaker at the 13th Annual Drug Store News Industry Issue Summit on Nov. 29 in New York.

"Pawlenty’s experience in financial management and cultivating economic development makes him a strategic addition to RedPrairie’s existing board of tenured and innovative business leaders," the company stated.

"Tim’s combination of experience in the public and private sectors makes him an exceptional addition to RedPrairie’s board of directors," stated RedPrairie CEO and fellow board member Mike Mayoras. "Tim and RedPrairie share a track record of strong financial performance, a passion for innovation and a commitment to advancing the interests of those we serve."

"I’m impressed with RedPrairie’s visionary strategy," Pawlenty said. "Their unique position in this market, at the intersection of supply chain and all-channel commerce, is compelling. RedPrairie is at the forefront of the movement to connect the supply chain and consumers in this rapidly evolving global economy. I’m looking forward to being part of a company with such significant financial momentum and that is a force in driving change in the software industry."

During his time as governor of Minnesota, Pawlenty oversaw the interests of 5.2 million citizens and was responsible for a $50 billion biennial budget, 30,000 employees and more than 20 agencies and departments. As governor, Pawlenty oversaw economic development efforts on behalf of Minnesota businesses, including the promotion of international business through trade missions to nine countries.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Mylan settles with Warner Chilcott over generic version of Femcon Fe

BY Alaric DeArment

PITTSBURGH — Generic drug maker Mylan has settled with Warner Chilcott in a case concerning an oral contraceptive.

Mylan said Wednesday that it and Famy Care had entered into an agreement with Warner Chilcott resolving a lawsuit over Femcon Fe (norethindrone and ethinyl estradiol chewable tablets, ferrous fumarate tablets).

Under the settlement, the litigation has been dismissed, and Mylan can begin marketing and selling a generic version of the drug once it receives approval from the Food and Drug Administration. Additional details of the settlement are confidential, Mylan said.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?